Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note issued on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Performance

Shares of NASDAQ AKTX opened at $3.83 on Friday. Akari Therapeutics has a 52 week low of $1.08 and a 52 week high of $4.40. The business has a 50-day simple moving average of $3.51 and a two-hundred day simple moving average of $2.46.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.